NASDAQ: LSTA
Lisata Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for LSTA

Based on 1 analyst offering 12 month price targets for Lisata Therapeutics Inc

Min Forecast
$15.00+228.23%
Avg Forecast
$15.00+228.23%
Max Forecast
$15.00+228.23%

Should I buy or sell LSTA stock?

Based on 1 analyst offering ratings for Lisata Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LSTA stock forecasts and price targets.

LSTA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-21

1 of 1

Forecast return on equity

Is LSTA forecast to generate an efficient return?

Company
N/A
Industry
349.4%
Market
203.54%

Forecast return on assets

Is LSTA forecast to generate an efficient return on assets?

Company
N/A
Industry
120.28%

LSTA earnings per share forecast

What is LSTA's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.98
Avg 2 year Forecast
-$0.67
Avg 3 year Forecast
-$1.00

LSTA revenue forecast

What is LSTA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$10.2M+853.27%
Avg 3 year Forecast
$7.3M+586.36%
LSTA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LSTA revenue growth forecast

How is LSTA forecast to perform vs Biotechnology companies and vs the US market?

Company
110.32%
Industry
116.73%
Market
23.58%
LSTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LSTA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LSTA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LSTA$4.57$15.00+228.23%Buy
ATNM$1.29N/AN/A
ESLA$1.07$16.00+1,395.33%Strong Buy
TVRD$4.31$38.00+781.67%Strong Buy
ATRA$5.56$6.00+7.91%Hold

Lisata Therapeutics Stock Forecast FAQ

Is Lisata Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LSTA) stock is to Buy LSTA stock.

Out of 1 analyst, 0 (0%) are recommending LSTA as a Strong Buy, 1 (100%) are recommending LSTA as a Buy, 0 (0%) are recommending LSTA as a Hold, 0 (0%) are recommending LSTA as a Sell, and 0 (0%) are recommending LSTA as a Strong Sell.

If you're new to stock investing, here's how to buy Lisata Therapeutics stock.

What is LSTA's earnings growth forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.67%.

Lisata Therapeutics's earnings in 2026 is -$18,242,000.On average, 4 Wall Street analysts forecast LSTA's earnings for 2026 to be -$8,637,262, with the lowest LSTA earnings forecast at -$8,298,546, and the highest LSTA earnings forecast at -$8,891,299. On average, 4 Wall Street analysts forecast LSTA's earnings for 2027 to be -$5,938,117, with the lowest LSTA earnings forecast at -$5,705,250, and the highest LSTA earnings forecast at -$6,112,768.

In 2028, LSTA is forecast to generate -$8,817,205 in earnings, with the lowest earnings forecast at -$8,471,432 and the highest earnings forecast at -$9,076,534.

What is LSTA's revenue growth forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's forecast annual revenue growth rate of 110.32% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.58%.

Lisata Therapeutics's revenue in 2026 is $1,070,000.On average, 3 Wall Street analysts forecast LSTA's revenue for 2026 to be $0, with the lowest LSTA revenue forecast at $0, and the highest LSTA revenue forecast at $0. On average, 4 Wall Street analysts forecast LSTA's revenue for 2027 to be $89,971,477, with the lowest LSTA revenue forecast at $86,443,183, and the highest LSTA revenue forecast at $92,617,697.

In 2028, LSTA is forecast to generate $64,779,463 in revenue, with the lowest revenue forecast at $62,239,092 and the highest revenue forecast at $66,684,741.

What is LSTA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LSTA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 120.28%.

What is LSTA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LSTA price target, the average LSTA price target is $15.00, with the highest LSTA stock price forecast at $15.00 and the lowest LSTA stock price forecast at $15.00.

The Wall Street analyst predicted that Lisata Therapeutics's share price could reach $15.00 by Aug 21, 2026. The average Lisata Therapeutics stock price prediction forecasts a potential upside of 228.23% from the current LSTA share price of $4.57.

What is LSTA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LSTA) Lisata Therapeutics's current Earnings Per Share (EPS) is -$2.13. On average, analysts forecast that LSTA's EPS will be -$0.98 for 2026, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$1.01. On average, analysts forecast that LSTA's EPS will be -$0.67 for 2027, with the lowest EPS forecast at -$0.65, and the highest EPS forecast at -$0.69. In 2028, LSTA's EPS is forecast to hit -$1.00 (min: -$0.96, max: -$1.03).

What is LSTA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LSTA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.